Inspiro Medical was acquired by OPKO Health, Inc. in April 2014.
Inspiro’s proprietary DPI is the first device to combine an active dry powder fluidization mechanism that works at low inhalation flow rates with a unique real-time feedback control and data logger indicating proper inhalation technique and follow-up.
Inspiromatic assures optimal drug delivery. Young children and the elderly will particularly benefit from the advantages of Inspiro’s dry powder inhalation.
Inhalers, including metered dose inhalers (MDIs), DPIs, and nebulizers, are often less than effective in delivering the necessary medication. The optimal delivery device aims for the most efficient and effective deposition of aerosol medication, accounting for drug particle/droplet size and the patient’s ability to understand and use the device.
MDIs require hand-breath coordination. DPIs are breath actuated and may require forceful inhalation. Many patients do not use these devices properly because of the complexities. With nebulizers, treatment time is relatively long, setup is cumbersome, and the apparatus is usually bulky and inconvenient.
Inspiro’s smart DPI designed for the treatment of pulmonary diseases such as asthma and chronic obstructive pulmonary disease (COPD).